Published in World J Hepatol on July 18, 2017
The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care (1992) 144.02
A 12-Item Short-Form Health Survey: construction of scales and preliminary tests of reliability and validity. Med Care (1996) 70.87
EuroQol--a new facility for the measurement of health-related quality of life. Health Policy (1990) 59.70
Sorafenib in advanced hepatocellular carcinoma. N Engl J Med (2008) 54.30
The European Organization for Research and Treatment of Cancer QLQ-C30: a quality-of-life instrument for use in international clinical trials in oncology. J Natl Cancer Inst (1993) 38.99
EuroQol: the current state of play. Health Policy (1996) 27.78
Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol (2008) 23.93
Liver transplantation for the treatment of small hepatocellular carcinomas in patients with cirrhosis. N Engl J Med (1996) 22.46
The Functional Assessment of Cancer Therapy scale: development and validation of the general measure. J Clin Oncol (1993) 18.75
EQ-5D: a measure of health status from the EuroQol Group. Ann Med (2001) 18.69
Development of the World Health Organization WHOQOL-BREF quality of life assessment. The WHOQOL Group. Psychol Med (1998) 13.87
SF-36 health survey update. Spine (Phila Pa 1976) (2000) 12.41
Prognosis of hepatocellular carcinoma: the BCLC staging classification. Semin Liver Dis (1999) 12.31
Arterial embolisation or chemoembolisation versus symptomatic treatment in patients with unresectable hepatocellular carcinoma: a randomised controlled trial. Lancet (2002) 12.16
Interpreting the significance of changes in health-related quality-of-life scores. J Clin Oncol (1998) 9.89
Randomized controlled trial of transarterial lipiodol chemoembolization for unresectable hepatocellular carcinoma. Hepatology (2002) 9.76
The World Health Organization Quality of Life Assessment (WHOQOL): development and general psychometric properties. Soc Sci Med (1998) 8.67
Measuring the quality of life of cancer patients: a concise QL-index for use by physicians. J Chronic Dis (1981) 7.00
A new prognostic system for hepatocellular carcinoma: a retrospective study of 435 patients: the Cancer of the Liver Italian Program (CLIP) investigators. Hepatology (1998) 6.47
A prospective randomized trial comparing percutaneous local ablative therapy and partial hepatectomy for small hepatocellular carcinoma. Ann Surg (2006) 5.65
Randomized controlled trial of screening for hepatocellular carcinoma. J Cancer Res Clin Oncol (2004) 5.29
Measuring health-related quality of life in patients with hepatobiliary cancers: the functional assessment of cancer therapy-hepatobiliary questionnaire. J Clin Oncol (2002) 4.16
Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes (2007) 3.66
Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol (2013) 3.45
Prospective validation of the CLIP score: a new prognostic system for patients with cirrhosis and hepatocellular carcinoma. The Cancer of the Liver Italian Program (CLIP) Investigators. Hepatology (2000) 3.30
The prognostic significance of patient-reported outcomes in cancer clinical trials. J Clin Oncol (2008) 3.14
Meaningful change in cancer-specific quality of life scores: differences between improvement and worsening. Qual Life Res (2002) 3.09
Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet (2016) 2.57
Initial response to percutaneous ablation predicts survival in patients with hepatocellular carcinoma. Hepatology (2004) 2.54
The interpretation of scores from the EORTC quality of life questionnaire QLQ-C30. Qual Life Res (1996) 2.53
A new prognostic classification for predicting survival in patients with hepatocellular carcinoma. Groupe d'Etude et de Traitement du Carcinome Hépatocellulaire. J Hepatol (1999) 2.38
Cost-effectiveness analysis of liver resection versus transplantation for early hepatocellular carcinoma within the Milan criteria. Hepatology (2014) 2.11
Impact of surgery on quality of life in patients with hepatocellular carcinoma. World J Surg (2014) 2.06
Quality of life is predictive of survival in patients with unresectable hepatocellular carcinoma. Ann Oncol (2006) 2.04
Health utilities using the EQ-5D in studies of cancer. Pharmacoeconomics (2007) 1.94
Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA (2014) 1.80
Extent of liver resection influences the outcome in patients with cirrhosis and small hepatocellular carcinoma. Surgery (2002) 1.76
Geographic difference in survival outcome for advanced hepatocellular carcinoma: implications on future clinical trial design. Contemp Clin Trials (2009) 1.67
A tutorial on sensitivity analyses in clinical trials: the what, why, when and how. BMC Med Res Methodol (2013) 1.63
Prospective Longitudinal Assessment of Quality of Life for Liver Cancer Patients Treated With Stereotactic Body Radiation Therapy. Int J Radiat Oncol Biol Phys (2015) 1.49
Quality of life after surgical resection compared with radiofrequency ablation for small hepatocellular carcinomas. Br J Surg (2014) 1.41
Handling missing data in RCTs; a review of the top medical journals. BMC Med Res Methodol (2014) 1.35
High-dose tamoxifen in the treatment of inoperable hepatocellular carcinoma: A multicenter randomized controlled trial. Hepatology (2002) 1.32
Multicollinearity in prognostic factor analyses using the EORTC QLQ-C30: identification and impact on model selection. Stat Med (2002) 1.28
Long-acting octreotide versus placebo for treatment of advanced HCC: a randomized controlled double-blind study. Hepatology (2007) 1.19
A randomised phase II/III trial of 3-weekly cisplatin-based sequential transarterial chemoembolisation vs embolisation alone for hepatocellular carcinoma. Br J Cancer (2013) 1.17
Assessment of patient-reported clinical outcome in pancreatic and other hepatobiliary cancers: the FACT Hepatobiliary Symptom Index. J Pain Symptom Manage (2002) 1.12
Cost-effectiveness of doxorubicin-eluting beads versus conventional trans-arterial chemo-embolization for hepatocellular carcinoma. Dig Liver Dis (2016) 1.09
Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol (2005) 1.08
Quality of life as a prognostic factor of overall survival in patients with advanced hepatocellular carcinoma: results from two French clinical trials. Qual Life Res (2008) 1.08
Radioembolization for hepatocellular carcinoma: a review of the evidence and treatment recommendations. Am J Clin Oncol (2011) 1.06
Randomized controlled trial of tamoxifen in advanced hepatocellular carcinoma. J Clin Oncol (2005) 1.05
Quality of life in patients diagnosed with primary hepatocellular carcinoma: hepatic arterial infusion of Cisplatin versus 90-Yttrium microspheres (Therasphere). Psychooncology (2004) 1.04
Long acting octreotide in the treatment of advanced hepatocellular cancer and overexpression of somatostatin receptors: randomized placebo-controlled trial. World J Gastroenterol (2007) 1.03
Increased quality of life among hepatocellular carcinoma patients treated with radioembolization, compared with chemoembolization. Clin Gastroenterol Hepatol (2013) 1.02
Symptom concerns and quality of life in hepatobiliary cancers. Oncol Nurs Forum (2008) 1.02
Investigating the missing data mechanism in quality of life outcomes: a comparison of approaches. Health Qual Life Outcomes (2009) 1.01
Somatostatin receptor expression, tumour response, and quality of life in patients with advanced hepatocellular carcinoma treated with long-acting octreotide. Br J Cancer (2006) 1.01
A prospective longitudinal study of quality of life after resection of hepatocellular carcinoma. Arch Surg (2001) 1.01
Development of a questionnaire module to supplement the EORTC QLQ-C30 to assess quality of life in patients with hepatocellular carcinoma, the EORTC QLQ-HCC18. Eur J Cancer (2004) 0.99
Anatomical versus non-anatomical resection for hepatocellular carcinoma. Br J Surg (2015) 0.99
Treatment of advanced hepatocellular carcinoma with long-acting octreotide: a phase III multicentre, randomised, double blind placebo-controlled study. Eur J Cancer (2009) 0.99
Long-term oral branched chain amino acids in patients undergoing chemoembolization for hepatocellular carcinoma: a randomized trial. Aliment Pharmacol Ther (2004) 0.98
Quality of life after radiofrequency ablation combined with transcatheter arterial chemoembolization for hepatocellular carcinoma: comparison with transcatheter arterial chemoembolization alone. Qual Life Res (2006) 0.96
Quality-of-life assessment in palliative care. Lancet Oncol (2002) 0.96
Ethnic differences in the behavior of hepatocellular carcinoma. Cancer (1999) 0.95
Preservation of quality of life with doxorubicin drug-eluting bead transarterial chemoembolization for unresectable hepatocellular carcinoma: Longitudinal prospective study. J Gastroenterol Hepatol (2015) 0.94
Quality of life as a predictor of cancer survival among Chinese liver and lung cancer patients. Eur J Cancer (2007) 0.94
Health-related quality of life of chronic liver disease patients with and without hepatocellular carcinoma. J Gastroenterol Hepatol (2007) 0.94
The added value of quality of life (QoL) for prognosis of overall survival in patients with palliative hepatocellular carcinoma. J Hepatol (2012) 0.94
Pilot randomized trial of selective internal radiation therapy vs. chemoembolization in unresectable hepatocellular carcinoma. Liver Int (2015) 0.93
Quality of life after stereotactic body radiation therapy for primary and metastatic liver tumors. Int J Radiat Oncol Biol Phys (2007) 0.91
Health-related quality of life: Hepatocellular carcinoma, chronic liver disease, and the general population. Qual Life Res (2006) 0.90
Reduced quality of life of patients with hepatocellular carcinoma. Dig Liver Dis (2003) 0.89
Longitudinal quality of life assessment of patients with hepatocellular carcinoma after primary transarterial chemoembolization. J Vasc Interv Radiol (2010) 0.89
Proxy ratings of health related quality of life in patients with hepatocellular carcinoma. Qual Life Res (2005) 0.87
Health-related quality of life: return to baseline after major and minor liver resection. Surgery (2007) 0.84
Randomised double-blind trial of megestrol acetate vs placebo in treatment-naive advanced hepatocellular carcinoma. Br J Cancer (2011) 0.83
Quality of Life in Hepatocellular Carcinoma Patients Treated with Transarterial Chemoembolization. HPB Surg (2016) 0.83
Quality of life in patients with hepatocellular carcinoma received surgical resection. J Surg Oncol (2007) 0.82
Quality of life and survival analysis of patients undergoing transarterial chemoembolization for primary hepatic malignancies: a prospective cohort study. HPB (Oxford) (2012) 0.82
Quality-of-life assessment in a palliative care setting in Germany: an outcome evaluation. Int J Palliat Nurs (2009) 0.81
Phase II trial of palliative radiotherapy for hepatocellular carcinoma and liver metastases. J Clin Oncol (2013) 0.80
Chemoocclusion vs chemoperfusion for treatment of advanced hepatocellular carcinoma: a randomised trial. Eur J Surg Oncol (2005) 0.80
Quality of life and its associated factors in patients with hepatocellular carcinoma receiving one course of transarterial chemoembolization treatment: a longitudinal study. Oncologist (2012) 0.80
Sorafenib in hepatocellular carcinoma: prospective study on adverse events, quality of life, and related feasibility under daily conditions. Med Oncol (2012) 0.80
Psychopathological profile and health-related quality of life (HRQOL) in patients with hepatocellular carcinoma (HCC) and cirrhosis. Clin Exp Med (2013) 0.80
Cost-effectiveness of sorafenib as a first-line treatment for advanced hepatocellular carcinoma. Eur J Gastroenterol Hepatol (2015) 0.80
Mode of allocation and social demographic factors correlate with impaired quality of life after liver transplantation. Health Qual Life Outcomes (2015) 0.80
The relative net health benefit of liver resection, ablation, and transplantation for early hepatocellular carcinoma. World J Surg (2015) 0.79
Optimal cut points for quality of life questionnaire-core 30 (QLQ-C30) scales: utility for clinical trials and updates of prognostic systems in advanced hepatocellular carcinoma. Oncologist (2014) 0.79
Sorafenib with or without everolimus in patients with advanced hepatocellular carcinoma (HCC): a randomized multicenter, multinational phase II trial (SAKK 77/08 and SASL 29). Ann Oncol (2016) 0.79
Health-related quality of life evaluated by tumor node metastasis staging system in patients with hepatocellular carcinoma. World J Gastroenterol (2012) 0.79
Assessment of symptom experience in patients undergoing hepatic resection or ablation. Cancer (2006) 0.78
Thymostimulin versus placebo for palliative treatment of locally advanced or metastasised hepatocellular carcinoma: a phase III clinical trial. BMC Cancer (2010) 0.78
Validation of the Japanese version of the EORTC hepatocellular carcinoma-specific quality of life questionnaire module (QLQ-HCC18). Health Qual Life Outcomes (2012) 0.78
Health-related quality of life in patients with hepatocellular carcinoma: the mediation effects of illness perceptions and coping. Psychooncology (2012) 0.77